HOME >> MEDICINE >> NEWS
Wilmington chemist wins national award for drug development

Chemist Paul S. Anderson of Lansdale, Pa., will be honored April 3 by the world's largest scientific society for directing the development of such drugs as Zocor for high cholesterol, Trusopt for glaucoma, and Crixivan and Sustiva for HIV. He will receive the 2001 Award in Industrial Chemistry from the American Chemical Society at its 221st national meeting in San Diego.

In a career that has involved shepherding Merck and DuPont pharmaceuticals from laboratory to market, Anderson concludes it's "a strong sense of community values" that makes the difference in drug discovery.

"That's what makes teams of researchers thrive," explained Anderson, the senior vice president of chemical and physical sciences at DuPont Pharmaceuticals Co. "You know somewhere in that sea of possibilities there is an answer. It comes when different people make little discoveries, share information, and work together to add it all up."

The discoveries of Crixivan and Sustiva, drugs that attack human immunodeficiency virus, each required the teamwork of over 100 experts, Anderson said from his Wilmington, Del., office.

"Both discovery processes were incredibly frustrating. Some molecules we made weren't soluble enough, others not potent enough, broke down too rapidly or couldn't get blood levels high enough to really attack HIV," he said.

Each project team tried and discarded about 1,000 drug candidates before Crixivan, a protease inhibitor, and Sustiva, a reverse transcriptase inhibitor, made it to market in 1996 and 1998, respectively.

Himself a medicinal chemist, Anderson said the project groups he directs are now developing the second generation of AIDS-fighting drugs. One is in Phase I and another in Phase II clinical trials.

Anderson said it was his father, a school superintendent, who sparked his career interest: "I remember we used to do kitchen-sink experiments at home while I was still in grade school," he said. "It got me really comfort
'"/>

Contact: Rodney Pearson
r_pearson@acs.org
202-872-4400
American Chemical Society
25-Mar-2001


Page: 1 2

Related medicine news :

1. NJIT chemistry professor edits text outlining best laboratory practices
2. Changing chemistry helps explain estrogen threat to the heart
3. Sealing corneal incisions with a drop of chemistry, BU researchers develop gel for cataract surgery
4. Herbal supplements testing topic of discussion at chemistry meeting March 30
5. Hopkins Peter Agre receives 2003 Nobel Prize in chemistry
6. Three Abbott chemists honored as Heroes for development of HIV therapy for children
7. Oregon State chemist wins national award for synthesizing molecules in nature
8. Chicago chemist wins national award for insights into how cells communicate
9. Irvine chemist wins national award for new drug techniques
10. Chicago chemist wins national award for new ways to make drug candidates
11. Illinois chemist wins national award for new drug research

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Wilmington chemist wins national award for drug development

(Date:5/29/2015)... Clarkston, Metamora, Michigan (PRWEB) May 29, 2015 ... vulvar region and can cause significant physical, sexual, and ... major life altering disorder of Vulvodynia. The actual diagnosis ... Women’s Excellence in Endometriosis, they realize that this problem ... patient is experiencing any of these symptoms, they need ...
(Date:5/29/2015)... CA (PRWEB) May 29, 2015 For the ... (USAU) to bring the Denver youth ultimate community an opportunity ... learning and individual improvement. The mission of the USAU Nike ... boys and girls to improve, build character, and make lifelong ... for boys and girls of all skill and ability levels, ...
(Date:5/29/2015)... External Counterpulsation, also known as EECP ... patients. The Heart Fit Clinic is the first clinic in ... review from patients who are now completing treatment. , ... treatments of ECP treatment and received great results. His ... does the clinic perform this non-surgical treatment for heart disease, ...
(Date:5/29/2015)... An organizational consultant and part-time college professor, Dr. ... and may be suffering from early dementia. He is ... and in his uncertain relationship with his wife Addie. ... with corporate and government movers and shakers as they ... around him are being diagnosed with Alzheimer’s, Ben wonders ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 Testosterone Centers of ... DFW area, is opening a new center in the Mid-Cities ... rest of the Mid Cities. Located on the south side ... in Hurst, the new testosterone center will open in May ... who suffer from low testosterone. , Like TCT’s other testosterone ...
Breaking Medicine News(10 mins):Health News:US Sports Camps, Nike Sports Camps, and USA Ultimate Host Third Summer of Ultimate Camp in Denver 2Health News:External Counterpulsation at Heart Fit Clinic Receives Raving Review 2Health News:‘Forgetful’ Professor Struggles With Dementia in Compelling New Novel 2Health News:Testosterone Clinics in Colleyville — TCT opens Hurst Location 2Health News:Testosterone Clinics in Colleyville — TCT opens Hurst Location 3
(Date:5/29/2015)... Lilly and Company (NYSE: LLY ) and AstraZeneca ... entered into a clinical trial collaboration to evaluate the ... checkpoint inhibitor, MEDI4736, in combination with CYRAMZA ® ... planned study will assess the combination as a treatment ... Phase I study is expected to establish the safety ...
(Date:5/28/2015)... 2015  Eli Lilly and Company (NYSE: LLY ) ... tender offer for up to $1.6 billion aggregate principal amount ... of notes who tendered, and did not validly withdraw, their ... City time, on May 27, 2015 (the early ... are eligible to receive the total consideration. The total consideration ...
(Date:5/28/2015)... 2015 Research and ... of Jain PharmaBiotech,s new report  "RNAi - ... offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... involves the use of double stranded RNA ... is processed into short 21-23 nucleotide RNAs ...
Breaking Medicine Technology:Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 2Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 4Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 6Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 7Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 8Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 9Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 10Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 11Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 12Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 13Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 14Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 2Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 3
Cached News: